| Drug Name |
Dihydroergotamine |
| Drug ID |
BADD_D00671 |
| Description |
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines.[L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile.
Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity.[A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product. |
| Indications and Usage |
Dihydroergotamine (DHE) in all formulations is indicated for the acute treatment of migraine with or without aura in adults.[L38459, L38464, L38469] As an injection, DHE is also indicated for the acute treatment of cluster headache episodes.[L38459]
DHE is not indicated for migraine prevention or the management of hemiplegic or basilar migraine.[L38459, L38464, L38469] |
| Marketing Status |
approved; investigational |
| ATC Code |
N02CA01 |
| DrugBank ID |
DB00320
|
| KEGG ID |
D07837
|
| MeSH ID |
D004087
|
| PubChem ID |
10531
|
| TTD Drug ID |
D0V3ZA
|
| NDC Product Code |
69238-1606; 47848-052 |
| UNII |
436O5HM03C
|
| Synonyms |
Dihydroergotamine | Clavigrenin | D-Tamin Retard L.U.T. | D Tamin Retard L.U.T. | DET MS | DHE-45 | DHE 45 | DHE45 | D.H.E. 45 | DHE-Puren | DHE Puren | DHE-Ratiopharm | DHE Ratiopharm | Dihydroergotamin AL | Dihydroergotamine Mesylate | Mesylate, Dihydroergotamine | Dihydroergotamine Methanesulfonate | Methanesulfonate, Dihydroergotamine | Dihytamin | Erganton | Ergomimet | Ergont | Ergotam Von Ct | Von Ct, Ergotam | Ikaran | Migranal | Dihydergot | Dihydroergotamine-Sandoz | Dihydroergotamine Sandoz | Orstanorm | Seglor | Agit | Tamik | Verladyn | Angionorm |
